Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease? Implications for therapeutic blockade of the renin-angiotensin system.
about
Angiotensin receptor blockers and myocardial infarctionMetabolic actions of angiotensin II and insulin: a microvascular endothelial balancing actParadoxical role of angiotensin II type 2 receptors in resistance arteries of old rats.Cardiovascular outcomes in high-risk patients without heart failure treated with ARBs: a systematic review and meta-analysis.Angiotensin receptor blockers and risk of myocardial infarction: systematic review.Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis.Angiotensin-converting enzymes and drug discovery in cardiovascular diseases.Foetal hypoxia increases cardiac AT(2)R expression and subsequent vulnerability to adult ischaemic injury.Angiotensin II receptors and drug discovery in cardiovascular disease.IL-1β and IL-18: inflammatory markers or mediators of hypertension?Dietary calcium intake and renin angiotensin system polymorphisms alter the blood pressure response to aerobic exercise: a randomized control design.From bedside to bench to bedside: role of renin-angiotensin-aldosterone system in remodeling of resistance arteries in hypertension.Valsartan in chronic heart failure.Clinical trial update: focus on the ONTARGET studyAngiotensin II type 1 receptor blockers as a first choice in patients with acute myocardial infarction.Valsartan in the treatment of heart attack survivorsComplications of hypertension and the role of angiotensin receptor blockers in hypertension trials.Vascular benefits of angiotensin receptor blockers.Candesartan in heart failure.Reduced Kidney Function Is Associated With Cardiometabolic Risk Factors, Prevalent and Predicted Risk of Cardiovascular Disease in Chinese Adults: Results From the REACTION Study.Lessons from ONTARGET.FXR an emerging therapeutic target for the treatment of atherosclerosisAdapter proteins and promoter regulation of the angiotensin AT2 receptor--implications for cardiac pathophysiology.Proteolysis of apolipoprotein A-I by secretory phospholipase A₂: a new link between inflammation and atherosclerosisPathogen burden, inflammation, proliferation and apoptosis in human in-stent restenosis. Tissue characteristics compared to primary atherosclerosis.Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials.Novel pathways and therapies in experimental diabetic atherosclerosis.Renin inhibitors and cardiovascular and renal protection: an endless quest?Renin inhibition in the treatment of diabetic kidney disease.Different cross-talk sites between the renin-angiotensin and the kallikrein-kinin systems.The pathobiology of diabetic vascular complications--cardiovascular and kidney disease.Update on the role of angiotensin in the pathophysiology of coronary atherothrombosis.Valsartan blocked alcohol-induced, Toll-like receptor 2 signaling-mediated inflammation in human vascular endothelial cells.Renin-Angiotensin System and AtrialFibrillation:Understanding the Connection.The vasoprotective axes of the renin-angiotensin system: Physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases.The Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Patients With Diabetes.Cardiovascular and cerebrovascular outcomes in elderly hypertensive patients treated with either ARB or ACEI.Divergent effects of losartan and metoprolol on cardiac remodeling, c-kit+ cells, proliferation and apoptosis in the left ventricle after myocardial infarctionAngiotensin receptor blockers and myocardial infarction: cautions voiced are biologically credible.Effect of unilateral ureteral obstruction and anti-angiotensin II treatment on renal tubule and interstitial cell apoptosis in rats.
P2860
Q24559659-49DB5B9F-AE34-4CF6-9E9C-03DF20434710Q28390079-ED623D5C-E40A-4F78-A6DD-C21008BF1351Q30481218-E916D3DB-84BD-4BBF-9D4B-C143A9B52642Q33403831-3BBE6869-F23E-4A16-941D-FC885371AAF1Q34081519-C0EE1E17-D757-4CA3-9970-67FF47726CCEQ34380070-782A53CB-48F4-4201-BEDA-F69C176F988CQ34423315-C1BE7B96-3B58-4855-A0E5-ADE5648F1855Q34485828-8F8F03EB-A34A-492F-8BF6-D617E6D98A3AQ34496676-7B22BADB-2E38-44A5-A01E-9066385E2F39Q34914125-7695DB2D-30DC-4C51-84B5-9A883185F64FQ35605319-F7B0D344-9F97-4BB0-BEE9-C4541526A581Q35847323-225A6FBD-0D13-4FFD-B874-1077A6BD59AAQ36027661-06D963DC-FC29-4136-BB16-35062F70AFF9Q36596857-5B3DBB58-52FF-41B5-87B7-8AF64F0FF4F6Q36638095-C39D8B05-6F77-4691-BDE2-DAEEF3B453D7Q36744015-CEC35F20-E2A0-4C45-A8E7-C1B8478DC09AQ36815965-FC0018EC-018F-479D-BAB0-0F4918221914Q36861584-BA9F5B7D-5CFA-486E-8304-4D2232B7B4B6Q37018943-369916CD-BC7F-4961-8B23-BCE4A3F7337CQ37240652-A44BD5A2-E8E6-4D00-94FF-21FC2DD4FBC5Q37247749-B5FEBC92-682B-453D-A799-623FD5983EFFQ37334984-CA4D4DD9-BEA1-4CC2-AD7C-060A49E9DAF4Q37598488-7ABE4205-B44B-45D0-9D65-D55C22B01BE2Q37683292-1CE79BE3-13AA-4935-BDEE-A027BF88C91EQ37866127-4BE8CA38-C88B-4E4A-B2E8-3E3741E5EA0DQ37869264-AEDD3A20-5234-47D3-B5D1-0B350BB249C9Q37990618-4BED82AD-C681-4D86-BF5C-FF2E1DB80416Q37990796-20941BF2-4603-4A20-A19D-7E166F25CEC0Q38075571-5E8C819E-7759-4586-9FAA-1524BBF9C062Q38079544-432B6AC3-C7B6-4070-8B95-692009AEE77CQ38200957-41B81530-F1B3-4AB3-B9AE-03A46123A461Q38317550-AB673D94-4C89-486D-A919-419462E23752Q38944982-87879B89-6D8C-44C2-9AF6-588CEDD1384DQ39300695-1DE57C65-A4C1-4C1D-ABDD-EC4C3F79F628Q39376362-8155A54A-6BB0-4474-B5A3-D07852147A38Q41469746-6DCD8A36-13D0-4214-8DE5-6795E13773EDQ41915019-2E8F0B19-136D-4FF3-BF6D-E2162C0CD596Q42123922-B638410B-E673-46E1-ADB6-149301816CC7Q43060502-BDE23248-D606-402D-99DD-E467981714FDQ43243640-70CD4261-8558-4FA0-BE42-E0EE3A6D56EF
P2860
Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease? Implications for therapeutic blockade of the renin-angiotensin system.
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
name
Can angiotensin II type 2 rece ...... the renin-angiotensin system.
@ast
Can angiotensin II type 2 rece ...... the renin-angiotensin system.
@en
Can angiotensin II type 2 rece ...... the renin-angiotensin system.
@nl
type
label
Can angiotensin II type 2 rece ...... the renin-angiotensin system.
@ast
Can angiotensin II type 2 rece ...... the renin-angiotensin system.
@en
Can angiotensin II type 2 rece ...... the renin-angiotensin system.
@nl
prefLabel
Can angiotensin II type 2 rece ...... the renin-angiotensin system.
@ast
Can angiotensin II type 2 rece ...... the renin-angiotensin system.
@en
Can angiotensin II type 2 rece ...... the renin-angiotensin system.
@nl
P1433
P1476
Can angiotensin II type 2 rece ...... the renin-angiotensin system.
@en
P2093
Bernard I Lévy
P356
10.1161/01.CIR.0000096609.73772.C5
P407
P577
2004-01-01T00:00:00Z